MabPlex is a leading contract development and manufacturing organization (CDMO) offering end-to-end services from gene sequence to finished biopharmaceutical product. With expertise in monoclonal (including bispecific) antibodies, antibody-drug conjugates and other recombinant proteins, we can accelerate your projects at every step, including cell line development, upstream and downstream process development, and formulation development Рwith fully compliant GMP operations. With three state-of-the-art sites in Yantai, Shanghai and San Diego, we have the facilities and expertise to support our clients globally. At MabPlex, we are committed to delivering high-quality product on-time with exceptional value.

Development

CMO cGMP Manufacturing

ADCs Analytical Solutions

QMS Quality and Regulatory

MabPlex Congratulates Encure Biopharma with FDA IND Clearance of YH001 for the Treatment of a Broad Range of Cancers

November 13, 2019
MabPlex International Ltd. confirms securing United States Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for Encure Biopharma...
Read More

MabPlex Lauded by Frost & Sullivan for Global Expansion of ADC Contract Manufacturing Services

October 10, 2019
Based on its recent analysis of the global antibody drug conjugate (ADC) contract manufacturing services market, Frost & Sullivan has...
Read More

MabPlex International Announces Appointment of Dr. Wei Chen (Ph.D) as Chief Executive Officer

August 11, 2019
MabPlex International Ltd (MabPlex) has appointed Wei Chen Ph.D as the company's new Chief Executive Officer (CEO). Dr. Chen, a...
Read More
X
INFORMATION